This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tada, Y. Articles by Kuwano, M. Search for Related Content PubMed PubMed Citation Articles by Tada, Y. Articles by Kuwano, M.

MDR1 Gene Overexpression and Altered Degree of Methylation at the Promoter Region in Bladder Cancer during Chemotherapeutic Treatment¹

Departments of Medical Biochemistry [Y. T., M. W., T. H., J. N., M. K.], Urology [K. K., S. N.], and Medical Informatics [N. K.], Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582; and Department of Urology [M. N.], Faculty of Medicine, Kagoshima University, Kagoshima 890-8520, Japan

Overexpression of the multidrug resistance 1 (MDR1) gene is closely associated with the clinical outcome of hematopoietic malignancies, but the alteration of its expression during chemotherapeutic treatment and the precise mechanism underlying MDR1 gene overexpression in solid tumors remains unclear. We determined the expression and degree of methylation at the promoter of the MDR1 gene in bladder cancer. The mRNA levels of the MDR1 gene were found to be markedly enhanced, 3.5- to 5.7-fold higher in bladder cancers after chemotherapeutic treatment than those in untreated primary tumors. The MDR1 gene was overexpressed in recurrent tumors in 89% of patients who showed re-recurrence, whereas overexpression was observed in 25% of the patients without re-recurrence. A statistically significant inverse correlation existed between MDR1 expression and the methylation of 5'CpG sites at the promoter in patients with bladder cancer after chemotherapeutic treatment, with the degree of methylation at several CpG sites, rather than other specific sites, involved in this regulation. Consistent with the increase in MDR1 expression, the frequency of patients with a hypermethylated promoter decreased to 50 and 17% after intravesical and systemic chemotherapy, respectively. Thus, overexpression of the MDR1 gene might be a prognostic marker for intravesical recurrence, whereas methylation of the promoter region negatively regulates MDR1 expression and the appearance of multidrug resistance mediated by P-glycoprotein in bladder cancers.

This article has been cited by other articles:

				L. M. Huff, J.-S. Lee, R. W. Robey, and T. Fojo Characterization of Gene Rearrangements Leading to Activation of MDR-1 J. Biol. Chem., December 1, 2006; 281(48): 36501 - 36509. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. Kobunai, E. Toda, Y. Yamamoto, T. Kanazawa, Y. Kazama, J. Tanaka, T. Tanaka, T. Konishi, Y. Okayama, et al. Distal Colorectal Cancers with Microsatellite Instability (MSI) Display Distinct Gene Expression Profiles that Are Different from Proximal MSI Cancers Cancer Res., October 15, 2006; 66(20): 9804 - 9808. [Abstract] [Full Text] [PDF]

				H. Arbach, V. Viglasky, F. Lefeu, J.-M. Guinebretiere, V. Ramirez, N. Bride, N. Boualaga, T. Bauchet, J.-P. Peyrat, M.-C. Mathieu, et al. Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue: Effect of EBV Infection of Breast Cancer Cells on Resistance to Paclitaxel (Taxol) J. Virol., January 15, 2006; 80(2): 845 - 853. [Abstract] [Full Text] [PDF]

				P. J. Bastian, J. Ellinger, A. Wellmann, N. Wernert, L. C. Heukamp, S. C. Muller, and A. von Ruecker Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci Clin. Cancer Res., June 1, 2005; 11(11): 4097 - 4106. [Abstract] [Full Text] [PDF]

				R. J. Cote, P. W. Laird, and R. H. Datar Promoter Hypermethylation: A New Therapeutic Target Emerges in Urothelial Cancer J. Clin. Oncol., May 1, 2005; 23(13): 2879 - 2881. [Full Text] [PDF]

				H. Takane, D. Kobayashi, T. Hirota, J. Kigawa, N. Terakawa, K. Otsubo, and I. Ieiri Haplotype-Oriented Genetic Analysis and Functional Assessment of Promoter Variants in the MDR1 (ABCB1) Gene J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1179 - 1187. [Abstract] [Full Text] [PDF]

				H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, W. W. Bassett, J. W. Anast, L.-C. Li, S. Urakami, M. Terashima, et al. CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer Cancer Res., September 1, 2004; 64(17): 5956 - 5962. [Abstract] [Full Text] [PDF]

				S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF]

				S. Taniguchi, Y. Mochida, T. Uchiumi, T. Tahira, K. Hayashi, K. Takagi, M. Shimada, Y. Maehara, H. Kuwano, S. Kono, et al. Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon Mol. Cancer Ther., December 1, 2003; 2(12): 1351 - 1359. [Abstract] [Full Text] [PDF]

				M van Rijnsoever, F Grieu, H Elsaleh, D Joseph, and B Iacopetta Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands Gut, December 1, 2002; 51(6): 797 - 802. [Abstract] [Full Text] [PDF]

				Y. Tada, M. Wada, K.-i. Taguchi, Y. Mochida, N. Kinugawa, M. Tsuneyoshi, S. Naito, and M. Kuwano The Association of Death-associated Protein Kinase Hypermethylation with Early Recurrence in Superficial Bladder Cancers Cancer Res., July 15, 2002; 62(14): 4048 - 4053. [Abstract] [Full Text] [PDF]

				G. Garcia-Manero, C. Bueso-Ramos, J. Daniel, J. Williamson, H. M. Kantarjian, and J.-P. J. Issa DNA Methylation Patterns at Relapse in Adult Acute Lymphocytic Leukemia Clin. Cancer Res., June 1, 2002; 8(6): 1897 - 1903. [Abstract] [Full Text] [PDF]